Shield Therapeutics PLC 1JS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.06
- Day Range
- €0.05–0.05
- 52-Week Range
- €0.05–0.41
- Bid/Ask
- €0.06 / €0.07
- Shares Outstanding
- 1.07B
- Market Cap
- £58.00M
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 68
Valuation
|
Metric
|
1JS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.17 |
Price/Cash Flow | — |
Price/Earnings
1JS
Financial Strength
|
Metric
|
1JS
|
|---|---|
Quick Ratio | 0.55 |
Current Ratio | 0.75 |
Interest Coverage | −0.64 |
Quick Ratio
1JS
Profitability
|
Metric
|
1JS
|
|---|---|
Return on Assets (Normalized) | −16.31% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −41.86% |
Return on Assets
1JS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|^Q&#rLmj | LOCK|!zVF? | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|fmN@CL%& | LOCK|Fdsdz | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|mF#v$! | LOCK|v^ | $40B | |||
| Zoetis Inc Class A
ZTS
| LOCK|t%!R<^l | LOCK|yX | $30B | |||
| Viatris Inc
VTRS
| LOCK|Jt>$&W% | LOCK|Bq | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|$& | LOCK|c>j | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|%?GV$>X | LOCK|^X | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|rc>N!& | LOCK|@m | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|&^F>W! | LOCK|$#$<Z | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Nyb%&yB | LOCK|#s | $2B |
United States